Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 391

1.

Digoxin and short term mortality after acute STEMI: Results from the MAGIC trial.

Metawee M, Charnigo R, Morales G, Darrat Y, Sorrell V, Di Biase L, Natale A, Delisle B, Elayi CS; and; Magic investigators.

Int J Cardiol. 2016 Sep 1;218:176-80. doi: 10.1016/j.ijcard.2016.05.022. Epub 2016 May 13.

PMID:
27236111
2.

Stunned myocardium after an anesthetic procedure in a pediatric patient - case report.

Faleiro Oliveira J, Rebelo Pacheco S, Moniz M, Nunes P, Abadesso C, Rebelo M, Loureiro H, Almeida H.

Rev Port Cardiol. 2016 Jun;35(6):375.e1-375.e5. doi: 10.1016/j.repc.2015.09.003. Epub 2016 May 11. English, Portuguese.

PMID:
27179636
3.

Digoxin Toxicity and Use of Digoxin Immune Fab: Insights From a National Hospital Database.

Hauptman PJ, Blume SW, Lewis EF, Ward S.

JACC Heart Fail. 2016 May;4(5):357-64. doi: 10.1016/j.jchf.2016.01.011. Epub 2016 Mar 30.

PMID:
27039127
4.

Use of Inotropic Agents in Treatment of Systolic Heart Failure.

Tariq S, Aronow WS.

Int J Mol Sci. 2015 Dec 4;16(12):29060-8. doi: 10.3390/ijms161226147. Review.

5.

New medical therapies for heart failure.

von Lueder TG, Krum H.

Nat Rev Cardiol. 2015 Dec;12(12):730-40. doi: 10.1038/nrcardio.2015.137. Epub 2015 Sep 29. Review.

PMID:
26416006
6.

Dialysate and serum potassium in hemodialysis.

Hung AM, Hakim RM.

Am J Kidney Dis. 2015 Jul;66(1):125-32. doi: 10.1053/j.ajkd.2015.02.322. Epub 2015 Mar 28. Review. Erratum in: Am J Kidney Dis. 2015 Nov;66(5):931. Dosage error in article text.

PMID:
25828570
7.

Pharmacogenetics of cardiac inotropy.

Lymperopoulos A, Garcia D, Walklett K.

Pharmacogenomics. 2014 Nov;15(14):1807-1821.

PMID:
25493572
8.

Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.

Yamashita T, Saitoh T, Matsushita M.

J Cardiol. 2015 Jul;66(1):69-72. doi: 10.1016/j.jjcc.2014.09.008. Epub 2014 Nov 6.

9.

Atrial fibrillation (acute onset).

Lip GY, Apostolakis S.

BMJ Clin Evid. 2014 Nov 27;2014. pii: 0210.

PMID:
25430048
11.

A patient with systolic dysfunction and an alternating axis.

Miller PE, Scholten EL, Desai CS, Tedford RJ.

JAMA Intern Med. 2014 Dec;174(12):2027-8. doi: 10.1001/jamainternmed.2014.5452. No abstract available.

PMID:
25347012
12.

Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure.

Piepoli M, Binno S, Villani GQ, Cabassi A.

Int J Cardiol. 2014 Sep 20;176(2):321-6. doi: 10.1016/j.ijcard.2014.07.085. Epub 2014 Aug 1. Review.

PMID:
25129309
13.

Digoxin-specific antibody fragments in the treatment of digoxin toxicity.

Chan BS, Buckley NA.

Clin Toxicol (Phila). 2014 Sep-Oct;52(8):824-36. doi: 10.3109/15563650.2014.943907. Epub 2014 Aug 4. Review.

PMID:
25089630
14.

[Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage].

Verdugo FJ, Montellano FA, Carreño JE, Marusic ET.

Rev Med Chil. 2014 Jan;142(1):61-71. doi: 10.4067/S0034-98872014000100010. Review. Spanish.

15.

Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.

Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Dimopoulou I, Iliodromitis E, Anastasiou-Nana M, Lainscak M, Ambrosio G, Mebazaa A, Filippatos G, Follath F.

Clin Res Cardiol. 2014 Sep;103(9):733-41. doi: 10.1007/s00392-014-0708-0. Epub 2014 Apr 10.

PMID:
24718849
16.

Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.

Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators.

Adv Ther. 2014 Apr;31(4):426-39. doi: 10.1007/s12325-014-0111-2. Epub 2014 Mar 19. Erratum in: Adv Ther. 2014 May;31(5):577-8.

17.

Drug therapy to reduce early readmission risk in heart failure: ready for prime time?

Vaduganathan M, Fonarow GC, Gheorghiade M.

JACC Heart Fail. 2013 Aug;1(4):361-4. doi: 10.1016/j.jchf.2013.04.010. Epub 2013 Aug 5.

PMID:
24621940
18.

Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.

Murin J, Naditch-Brûlé L, Brette S, Chiang CE, O'Neill J, Steg PG.

PLoS One. 2014 Jan 31;9(1):e86443. doi: 10.1371/journal.pone.0086443. eCollection 2014.

19.

The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry.

Garcia-Rubira JC, Calvo-Taracido M, Francisco-Aparicio F, Almendro-Delia M, Recio-Mayoral A, Reina Toral A, Aramburu-Bodas O, Gallego García de Vinuesa P, Cruz Fernández JM, Alcántara AG, Hidalgo-Urbano R.

Intern Emerg Med. 2014 Oct;9(7):759-65. doi: 10.1007/s11739-013-1032-9. Epub 2013 Dec 19.

PMID:
24352793
20.

Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure.

Ahmed A, Bourge RC, Fonarow GC, Patel K, Morgan CJ, Fleg JL, Aban IB, Love TE, Yancy CW, Deedwania P, van Veldhuisen DJ, Filippatos GS, Anker SD, Allman RM.

Am J Med. 2014 Jan;127(1):61-70. doi: 10.1016/j.amjmed.2013.08.027. Epub 2013 Nov 18.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk